💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak business, trading cheap versus its own history.
Hikal is scored on the pharma / healthcare framework. It keeps a thin -2.8% of every rupee of sales as net profit. It throws off free cash worth 5.8% of its market value — a strong free-cash yield.
Book value has been broadly flat (1.9%/yr). Return on equity is a weak 3.0%. In the latest quarter profit fell 151% versus the prior quarter.
At 21× earnings, the stock sits at the 1st percentile of its own 3-year range — the cheap end of where it has historically traded. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | -532.8 | — | — |
| P/B | 2.25 | 4.1 | better |
| EV/EBITDA | 16.42 | 19.33 | better |
| ROE | 3.03 | — | — |
| ROCE | 3.56 | 14.41 | worse |
| ROA | -0.21 | 1.64 | worse |
| Quick Ratio | 0.77 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue declined 8% in the latest year — a break from prior trajectory. Negative CAGR — the top line has shrunk over this window. Growth is decelerating — latest year grew slower than the year before.
1 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a -154% swing — check if it's a one-off or structural.
Operating margin has compressed from 5% to -5% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line.
Negative ROE — the business is destroying shareholder value. Capital efficiency declining — ROE down 11pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. 8% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 23% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (39% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 14% above earlier ones.
3 of 4 quarters loss-making — quarterly profitability is uneven. Profit fell 151% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly net margins are expanding (-11% → -2%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3y median.
Promoters hold 68.8% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.